Immunovant Inc (IMVT)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$30.53

+2.14 (+7.54%)

Market Cap: $5.86B

Last updated: Nov 06, 2026 at 4:10 PM ET

Earnings

Performance (10Y)

Beat Rate

33%(9/27)

Avg Surprise

-8.09%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.72

Range$-0.76 - $-0.70

3 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.53-37.3%

60d ago$-0.720.0%

30d ago$-0.720.0%

7d ago$-0.720.0%

Current$-0.72

Revenue Consensus

Range$0 - $0

12 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.67

Range$-0.77 - $-0.53

3 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.45-50.5%

60d ago$-0.670.0%

30d ago$-0.670.0%

7d ago$-0.670.0%

Current$-0.67

Revenue Consensus

Range$0 - $0

12 analysts

Last 12 of 30 reported quarters and 3 upcoming estimates

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Mar 31, 2027Mar 27EST	-	$-0.83	$-1.04 - $-0.51	-	-	5	-	-
Dec 31, 2026Dec 26EST	-	$-0.67	$-0.77 - $-0.53	-	-	3	0 1 30d	-
Sep 30, 2026Sep 26EST	-	$-0.72	$-0.76 - $-0.70	-	-	3	0 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-0.75	$-0.66	$-0.75 - $-0.48	-13.64%	Miss	2	1 0 30d	-5.6%
Mar 31, 2026Mar 26 Reported May 20, 2026Reported May 20	$-0.67	$-0.63	$-0.73 - $-0.53	-6.35%	Miss	5	2 0 30d	-4.7%
Dec 31, 2025Dec 25 Reported Feb 6, 2026Reported Feb 6	$-0.54	$-0.69	$-0.76 - $-0.57	+21.74%	Beat	9	1 0 30d	+28.9%
Sep 30, 2025Sep 25 Reported Nov 10, 2025Reported Nov 10	$-0.65	$-0.73	$-0.80 - $-0.59	+10.96%	Beat	13	2 5 30d	+12.2%
Jun 30, 2025Jun 25 Reported Aug 11, 2025Reported Aug 11	$-0.71	$-0.67	$-0.77 - $-0.57	-5.97%	Miss	10	3 0 30d	-18.3%
Mar 31, 2025Mar 25 Reported May 29, 2025Reported May 29	$-0.64	$-0.71	$-0.86 - $-0.56	+10.11%	Beat	10	No revisions (30d)	-23.1%
Dec 31, 2024Dec 24 Reported Feb 6, 2025Reported Feb 6	$-0.76	$-0.75	$-0.83 - $-0.56	-1.33%	Miss	9	1 0 30d	-111.1%
Sep 30, 2024Sep 24 Reported Nov 6, 2024Reported Nov 6	$-0.74	$-0.59	$-0.67 - $-0.46	-25.42%	Miss	14	1 0 30d	-64.4%
Jun 30, 2024Jun 24 Reported Aug 6, 2024Reported Aug 6	$-0.60	$-0.52	$-0.58 - $-0.46	-15.38%	Miss	10	No revisions (30d)	-5.3%
Mar 31, 2024Mar 24 Reported May 29, 2024Reported May 29	$-0.52	$-0.43	$-0.49 - $-0.35	-20.93%	Miss	14	No revisions (30d)	-13.0%
Dec 31, 2023Dec 23 Reported Feb 12, 2024Reported Feb 12	$-0.36	$-0.42	$-0.53 - $-0.30	+14.29%	Beat	13	No revisions (30d)	+26.5%
Sep 30, 2023Sep 23 Reported Nov 9, 2023Reported Nov 9	$-0.45	$-0.46	$-0.55 - $-0.34	+2.17%	Beat	12	2 0 30d	-9.8%

Key Metrics

Valuation
P/E Ratio	-11.70	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-80.10%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	7.27x	Quick Ratio	7.27x
Trading Statistics
Beta	0.94	Avg Volume	1.42M
52-Week High	$45.42	52-Week Low	$21.43

Technical Indicators Dashboard

Moving Averages

SMA 10$29.16

SMA 20$28.70

SMA 50$33.11

SMA 200$32.12

EMA 10$29.27

EMA 20$29.68

EMA 50$32.23

EMA 200$31.68

MACD

Line: -0.94Signal: -1.41Hist: 0.47

ADX

ADX: 30.9+DI: 18.1-DI: 21.4

Aroon & PSAR

Aroon UpN/A

Aroon Down40.0

PSAR$28.12

Bollinger Bands

Upper Band$30.48

Lower Band$26.92

%B Position1242%(Upper)

Band Width1.01

RSI (14-Day)

Neutral

51.1

Momentum Oscillators

Stoch %K80.8

Stoch %D75.4

Williams %R-2.7

ROC (10d)7.5%

Momentum2.12

CCI (20d)132.9

MFI (14d)70.7

Volatility Measures

ATR (14d)$1.31(4.3%)

StdDev (20d)0.89

Hist Vol49.9%(High)

Volume Flow

VWAP$29.83

OBV29.4M

AD Line28.6M

CMF (20d)0.015

Volume Metrics

Avg Vol (20d)1.4M

Vol Ratio1.9x(High)

VWMA (20d)$28.77

Pivot Points

R3$31.15

R2$30.49

R1$29.44

Pivot Point$28.78

S1$27.73

S2$27.07

S3$26.02

Advanced Oscillators

TSI-21.03

Ultimate Osc55.0

KST-117.82

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$7.09M	$0	$0	$0	$0	$160,000	$0	$0	$0	$1.50M	$0	$0
Cost of Revenue	N/A	N/A	$101,000	$105,000	$107,000	$80,000	$99,000	$89,000	$80,000	$64,000	$58,000	$349,000
Gross Profit	$7.09M	N/A	$-101,000	$-105,000	$-107,000	$80,000	$-99,000	$-89,000	$-80,000	$1.44M	$-58,000	$-349,000

Operating Expenses	$160.32M	$159.55M	$114.36M	$131.76M	$127.22M	$113.83M	$114.30M	$115.74M	$94.28M	$80.88M	$61.55M	$61.80M
R&D	$142.63M	$142.29M	$98.92M	$114.25M	$101.20M	$93.65M	$94.52M	$97.27M	$75.47M	$66.06M	$48.34M	$47.96M
SG&A	$17.69M	$17.27M	$15.44M	$17.51M	$26.02M	$20.17M	$19.78M	$18.47M	$18.81M	$14.82M	$13.21M	$13.84M
Operating Income	$-153,228,000	$-159,554,000	$-114,362,000	$-131,762,000	$-127,224,000	$-113,825,000	$-114,302,000	$-115,743,000	$-94,281,000	$-80,879,000	$-61,553,000	$-61,800,000

Interest Income	$7.09M	$8.06M	$5.33M	$5.60M	$6.34M	$6.89M	$4.59M	$6.07M	$7.18M	$8.38M	$8.93M	$3.57M
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-153,224,000	$-150,700,000	$-109,083,000	$-125,908,000	$-119,700,000	$-105,866,000	$-110,970,000	$-109,041,000	$-87,073,000	$-75,087,000	$-51,526,000	$-58,208,000
Income Tax Expense	$0	$-2,844,000	$1.55M	$594,000	$913,000	$583,000	$152,000	$78,000	$77,000	$232,000	$-108,000	$454,000

Net Income	$-153,224,000	$-147,856,000	$-110,635,000	$-126,502,000	$-120,613,000	$-106,449,000	$-111,122,000	$-109,119,000	$-87,150,000	$-75,319,000	$-51,418,000	$-58,662,000

EBITDA	$-153,132,000	$-150,604,000	$-108,982,000	$-125,803,000	$-119,593,000	$-105,757,000	$-110,871,000	$-108,952,000	$-86,993,000	$-75,023,000	$-51,468,000	$-58,152,000
EBIT	$-153,224,000	$-150,700,000	$-109,083,000	$-125,908,000	$-119,700,000	$-105,866,000	$-110,970,000	$-109,041,000	$-87,073,000	$-75,087,000	$-51,526,000	$-58,208,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about IMVT

News

(IMVT) Price Dynamics and Execution-Aware Positioning

This article provides an AI-generated analysis of Immunovant Inc. (NASDAQ: IMVT), highlighting strong near-term sentiment but elevated downside risk due to a lack of long-term support signals. It outlines specific...

Stock Traders Daily•Nov 1, 2026 6:54 PM ET11/1/26•Somewhat-Bullish

Immunovant | 4: Statement of changes in beneficial ownership of securities-Officer Girao Tiago

This article is a SEC Form 4 filing related to Immunovant, indicating a statement of changes in beneficial ownership of securities for officer Girao Tiago. The content suggests a standard regulatory disclosure without...

Moomoo•Oct 31, 2026 2:09 PM ET10/31/26•Neutral

Form 4 Immunovant Inc: Tiago Girao (CFO) For: 28 October By Investing.com

This article from Investing.com reports on a Form 4 filing for Immunovant Inc, indicating that Tiago Girao, the CFO, made a transaction on October 28. The brief update is a standard financial news item...

Investing.com Australia•Oct 31, 2026 12:27 AM ET10/31/26•Neutral

Form 4 Immunovant Inc: Jay S. Stout (CTO) For: 21 October By Investing.com

This article from Investing.com reports on a Form 4 filing for Immunovant Inc, specifically detailing an insider transaction by Jay S. Stout, the company's CTO...

Investing.com South Africa•Oct 25, 2026 3:40 AM ET10/25/26•Neutral

Immunovant CTO Jay Stout sells $75,099 in shares

Jay S. Stout, CTO of Immunovant, Inc., sold 2,595 shares of the company's common stock for $75,099 on October 21...

Investing.com India•Oct 24, 2026 2:11 AM ET10/24/26•Neutral

IMVT Valuation and Fair Value

P/E: -11.7x
P/B: 8.5x

See GNG's fair value

IMVT Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -80.1%

IMVT Competitors

Company	Ticker
Ligand Pharmaceuticals Incorporated	LGND
Grifols SA ADR	GRFS
Mirum Pharmaceuticals Inc	MIRM
CG Oncology, Inc. Common stock	CGON
RadNet Inc	RDNT
Kodiak Sciences Inc	KOD
Doximity Inc	DOCS
Haemonetics Corporation	HAE

Sector: Healthcare

IMVT Analyst Ratings

Consensus: Buy
Analysts: 17
Strong Buy: 2
Buy: 11
Hold: 4
Sell: 0
Strong Sell: 0

IMVT Bull Case vs Bear Case

Bull case

76.5% of IMVT's analyst ratings are Buy or Strong Buy.

Bear case

IMVT beat EPS estimates in 37.5% of its last 8 reported quarters.

IMVT Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -1.2%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.72
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 1 down

IMVT Earnings Date

IMVT reports Nov 9, 2026, before the open. The date is confirmed.

IMVT Earnings Call

The latest IMVT earnings call transcript on file is labeled 2026Q2.

Read the 2026Q2 transcript

IMVT ETF Holders

GNG tracks 16 ETFs that hold IMVT. The largest weights:

abrdn Healthcare Investors (HQH), 1.57% of the fund
State Street SPDR S&P Biotech ETF (XBI), 0.60% of the fund
iShares Biotechnology ETF (IBB), 0.17% of the fund
Fidelity Growth Company Fund (FDGRX), 0.17% of the fund
Fidelity Growth Company K6 Fund (FGKFX), 0.15% of the fund

Open the ETF Stock Exposure tool for IMVT

See insider activity

Frequently Asked Questions About IMVT

When does IMVT report earnings?

Immunovant Inc (IMVT) is confirmed to report earnings on Nov 9, 2026.

Does IMVT pay dividends?

Immunovant Inc (IMVT) does not currently pay a regular dividend.

What is IMVT's market cap?

Immunovant Inc (IMVT) has a market capitalization of $5.86B with a current stock price of $30.53.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In